RxDoctor Payments Data

Richelle Marasigan, DO

Family Medicine · Stockton, CANPI 1033408885

Payments from drug & device makers

$15,735in general payments, 2019–2025

Across 944 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • GSK$1K
  • AbbVie$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,62799%
  • Education$901%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)76$1,580
Novo Nordisk80$1,495
GSK96$1,351
AbbVie(2 entities)81$1,337
Boehringer Ingelheim71$1,174
Lilly USA, LLC83$1,108
Pfizer43$687
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC51$677
Johnson & Johnson55$597
Amgen26$494
Otsuka America Pharmaceutical, Inc.19$406
Vanda Pharmaceuticals Inc.16$377
Takeda Pharmaceuticals U.S.A., Inc.25$363
Merck19$333
Astellas Pharma US Inc13$311
Biohaven Pharmaceuticals, Inc.12$268
Mayne Pharma Commercial LLC4$222
Idorsia Pharmaceuticals US Inc22$210
Axsome Therapeutics, Inc.9$208
Exact Sciences9$204
Sumitomo Pharma America, Inc.10$182
Sunovion Pharmaceuticals Inc.13$143
Nestle Healthcare Nutrition Inc.8$130
Novartis7$127
Corcept Therapeutics5$106
Sanofi-aventis U.S. LLC7$105
Lundbeck LLC5$102
Aimmune Therapeutics, Inc.3$101
Medacta USA, Inc.1$93
Biohaven Pharmaceutical Holding Company Ltd.5$88
E.r. Squibb & Sons, L.L.C.5$85
Eisai Inc.5$85
Abbott4$75
Nabriva Therapeutics, PLC5$68
Teva Pharmaceuticals USA, Inc.4$54
Hologic Sales And Service, LLC3$49
Ironwood Pharmaceuticals, Inc3$45
Cranial Technologies, Inc3$42
Boston Scientific2$41
Esperion Therapeutics, Inc.2$34
Philips North America LLC2$32
Bayer2$32
Kowa Pharmaceuticals America, Inc.2$31
Phathom Pharmaceuticals, Inc.2$31
Electromed, Inc.2$31
Organogenesis Inc.1$25
Baxter Healthcare1$24
Hikma Pharmaceuticals USA2$23
Azurity Pharmaceuticals, Inc.1$23
Intra-sana Laboratories1$23
Sanofi1$22
Viatris Specialty LLC1$20
Covis Pharma GmbH1$20
Amarin Pharma, Inc.1$20
Arbor Pharmaceuticals, Inc.1$19
Verona Pharma, Inc.1$19
Sanofi Pasteur Inc.1$19
Biogen1$18
Qiagen, LLC1$18
Actelion Pharmaceuticals US, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,735 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$206,734
Medicare patients
379
Services billed
2,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide232$279,471
Trelegy ElliptaFluticasone/Umeclidin/Vilanter113$104,032
JardianceEmpagliflozin51$77,757
EliquisApixaban103$68,465
MounjaroTirzepatide38$54,015
LinzessLinaclotide24$30,116
WegovySemaglutide20$27,873
XareltoRivaroxaban21$26,771
RybelsusSemaglutide11$26,745
JanuviaSitagliptin Phosphate17$24,055
TradjentaLinagliptin19$19,205
MyrbetriqMirabegron26$16,667
GemtesaVibegron23$16,283
Nurtec OdtRimegepant Sulfate12$15,417
Tresiba Flextouch U-200Insulin Degludec11$9,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$1,495$334,089263 claims
GSKTrelegy Ellipta$1,351$104,032113 claims
Boehringer IngelheimJardiance, Tradjenta$1,174$96,96270 claims
PfizerEliquis, Nurtec Odt, Paxlovid$687$86,617126 claims
Lilly USA, LLCMounjaro$1,108$54,01538 claims
AbbVieLinzess, Synthroid$1,337$32,27957 claims
Johnson & JohnsonXarelto$597$26,77121 claims
MerckJanuvia$333$24,05517 claims
Astellas Pharma US IncMyrbetriq$311$16,66726 claims
Sumitomo Pharma America, Inc.Gemtesa$182$16,28323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →